Tumor angiogenesis.
Kerbel
Robert S
RS
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and the Department of Medical Biophysics, University of Toronto, Toronto. robert.kerbel@sri.utoronto.ca
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001854:Bone Marrow Cells / Q000502:physiology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology*; D011518:Proto-Oncogene Proteins / Q000502:physiology; D000074562:Receptor, Notch4; D051880:Receptors, Notch / Q000502:physiology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000502:physiology*; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology*
D020533:Angiogenesis Inhibitors; C106075:NOTCH4 protein, human; D011518:Proto-Oncogene Proteins; D000074562:Receptor, Notch4; D051880:Receptors, Notch; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor